Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 46

  • 1 201 clinical trials
  • 458 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia77Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Follicular lymphoma41Plasma cell myeloma refractory41Mantle cell lymphoma32Myelofibrosis31Chronic myeloid leukaemia29B-cell small lymphocytic lymphoma28Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17B-cell lymphoma refractory16B-cell type acute leukaemia16Paroxysmal nocturnal haemoglobinuria16Diffuse large B-cell lymphoma refractory14+340

Clinical trials in Blood and lymphatic system disorders

1 201 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 201 clinical trials

Sickle cell disease

Not yet recruiting

Study of GBT021601 for Adults and Children with Sickle Cell Disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:(S)-2-Hydroxy-6-((4-(2-(2-Hydroxyethyl)Nicotinoyl)Morpholin-3-Yl)Methoxy)Benzaldehyde
  • Sponsor:Global Blood Therapeutics Inc.

Acute myeloid leukaemia+2

Not yet recruiting

Study of EP0042 alone and in combination with venetoclax and azacitidine in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ellipses Pharma Limited

Polycythaemia vera

Not yet recruiting

Study on the Safety and Effectiveness of Peginterferon Alfa-2a and Ruxolitinib for Newly Diagnosed Polycythemia Vera Patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Region Sjaelland

Prostate cancer+1

Not yet recruiting

Study on Darolutamide, Triptorelin, and Leuprorelin Acetate for Patients with Newly Diagnosed Prostate Cancer and Pelvic Lymph Node Metastases

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:ARTIC

Plasma cell myeloma

Not yet recruiting

Study of ixazomib, iberdomide and dexamethasone combination in elderly patients with first relapse of multiple myeloma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Dexamethasone
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Chronic lymphocytic leukaemia

Not yet recruiting

Study on Lymph Node Changes in Chronic Lymphocytic Leukemia Patients Treated with Venetoclax

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Ospedale San Raffaele S.r.l.

Blood disorder

Not yet recruiting

Study on the Role of Vitamin D (Colecalciferol) in Preventing Graft-Versus-Host Disease in Patients Undergoing Stem Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Colecalciferol
  • Sponsor:Azienda Ospedaliero Universitaria Pisana

Plasma cell myeloma

Not yet recruiting

Study on Multiple Myeloma Treatment with Isatuximab, Lenalidomide, and Carfilzomib for Patients Under 66 Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Carfilzomib
  • Sponsor:Intergroupe Francophone Du Myelome

Lymphatic malformation

Not yet recruiting

Study on Sirolimus for Treating Cervico-facial Lymphatic Malformations in Patients with Poor Prognosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Sirolimus
  • Sponsor:Centre Hospitalier Universitaire De Lille

Anaemia of chronic disease

Not yet recruiting

Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Darbepoetin Alfa
  • Sponsor:Genexine Inc.

Acute myeloid leukaemia

Not yet recruiting

Study of venetoclax and mercaptopurine combination treatment for patients with relapsed or treatment-resistant acute myeloid leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mercaptopurine
  • Sponsor:Antwerp University Hospital

Acute myeloid leukaemia refractory+1

Not yet recruiting

Study on CCTx-001, Cyclophosphamide Monohydrate, and Fludarabine Phosphate for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cctx-001
  • Sponsor:CanCell Therapeutics

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab122 clinical trialsVenetoclax114 clinical trialsCyclophosphamide100 clinical trialsLenalidomide98 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.